Jan 7, 2013 by Max MacalusoWill This Biotech Dominate the Hepatitis-C Market?Will Gilead or AbbVie be crowned king?
Jan 7, 2013 by Max MacalusoBioMarin Goes ShoppingOrphan drugmaker BioMain takes a small bet on Zacharon pharma
Jan 7, 2013 by Max MacalusoWill Orexigen Have the Last Laugh? VIVUS and Arena have grabbed the spotlight recently, but can Orexigen get in the mix?
Jan 5, 2013 by Max Macaluso, Brenton Flynn, and Dave WilliamsonRisks MannKind Investors Need to KnowWhat are the major risks facing this biotech stock?
Jan 4, 2013 by Max Macaluso and Brenton FlynnDoes This Pharma Have Spinout Envy?While other big pharmas are spinning out businesses, Merck stays on course.
Jan 4, 2013 by Max Macaluso and Brenton Flynn2013 Focus for Biogen InvestorsWith Biogen's recent clinical trial failure, what should investors focus on now?
Jan 4, 2013 by Max MacalusoAre FDA Delays Good or Bad for Investors? FDA decisions can be hard to interpret ...
Jan 3, 2013 by Max Macaluso and Brenton FlynnWhat Hurt Ariad's Shares in December?FDA approvals should be good news, right?
Jan 3, 2013 by Max MacalusoWill More Data Make the Difference for Merck?Can Merck get its cholesterol drug approved?
Jan 3, 2013 by Max Macaluso, Brenton Flynn, and Dave WilliamsonThe Biggest (Potential) Turnaround Story in PharmaWhat risks will AstraZeneca need to overcome to turn itself around?
Jan 3, 2013 by Max Macaluso, Brenton Flynn, and Dave WilliamsonThe Most Annoying Story in BiotechWhen will the drama end?
Jan 3, 2013 by Max MacalusoWhat Hurt Amarin's Shares in December?After so much investor excitement, what caused December's Amarin sell-off?
Jan 2, 2013 by Max Macaluso and Brenton FlynnWhy Rigel Pharmaceuticals Lost Big in DecemberRigel Pharmaceuticals took a big hit in December. Here's why.
Dec 20, 2012 by Max Macaluso, Brenton Flynn, and Dave WilliamsonWas Buffett Wrong About This Blue Chip?Is holding on to all of Merck's departments the right move?
Dec 20, 2012 by Max Macaluso and Brenton FlynnWhy Shares of Amicus Cratered TodayThe biotech space is full of roller coasters, and Amicus is the latest.
Dec 20, 2012 by Max Macaluso and Brenton FlynnWhy Shares of Oncothyreon Imploded YesterdayOncothyreon was down big yesterday - what happened?
Dec 18, 2012 by Max Macaluso and Brenton Flynn2012 Review: Greenway Medical TechnologiesHow was 2012 for this new kid on the healthcare block?
Dec 18, 2012 by Max Macaluso and Brenton Flynn2012 Review: Merrimack PharmaceuticalsMerrimack Pharmaceuticals is up since its IPO, but where will it go from here?
Dec 18, 2012 by Max Macaluso and Brenton Flynn2012 in Review: TesaroLet's look at Tesaro's business and drug pipeline.
Dec 17, 2012 by Max Macaluso and Dave WilliamsonHold Your Horses, VIVUS InvestorsAnother pop from VIVUS today, but will it last?
